Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Dana-Farber Expand ICE COLD-PCR License

NEW YORK (GenomeWeb) — Transgenomic said today that it has signed a licensing deal with the Dana-Farber Cancer Institute for exclusive worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCR technology.

The new license covers all fields and applications of the multiplexed technology, enabling the simultaneous detection of multiple DNA mutations from a single liquid sample such as blood or urine, Transgenomic said.

The deal also expands on an existing license between Transgenomic and Dana-Farber for ICE COLD-PCR, which stands for "improved and complete enrichment-coamplification at lower denaturation temperature PCR" and was developed in the laboratory of Dana-Farber researcher Mike Makrigiorgos.

In 2009, Omaha, Neb.-based Transgenomic signed an exclusive licensing agreement with Dana-Farber to use COLD-PCR combined with Sanger sequencing and for mitochondrial DNA analysis. They followed that agreement in 2011 with an expanded license to include ICE COLD-PCR and the analysis of COLD-PCR products by pyrosequencing.

ICE COLD-PCR selectively focuses on only the mutated DNA in tumors that is useful for cancer diagnosis, monitoring, and treatment. It detects mutated DNA at 100- to 400-fold greater sensitivity than conventional approaches and enables identification of all tumor mutations, known and unknown, the company said.

"Multiplexing makes our ICE COLD-PCR technology far more efficient and allows us to assemble targeted panels of relevant mutations that can be simultaneously analyzed from a single sample," Transgenomic CEO Paul Kinnon said in a statement. "This should greatly increase its availability for routine use in cancer therapy, as well as for our biopharmaceutical customers who plan to use [multiplexed] ICE COLD-PCR to develop new cancer treatments and companion diagnostics."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.